Novo Nordisk's Pipeline Setback Collides With a Buyback Signal That Tells a Different Story

Novo Nordisk trades at a discount despite pipeline setbacks and Lilly competition; buybacks and regulatory wins in China and Europe signal management confidence.

The most telling detail about Novo Nordisk's current predicament isn't the Deutsche Bank downgrade that landed this week — it's the quiet contradiction playing out in the company's own share register. While one of Europe's largest banks was slashing its rating to "Sell," the Danish pharmaceutical giant was busy buying its own stock back at a pace that suggests management sees something the skeptics don't.

Between August 17 and 21, Novo Nordisk acquired 1,045,000 B-shares for 309.2 million Danish kroner, following a million-share purchase the previous week at an average price of 303.04 kroner. The buyback program, carrying a total envelope of 15 billion kroner, has now accumulated nearly 44 million B-shares — roughly one percent of the company's share capital. Add to that a dividend of $0.5786 per share paid on August 25 to shareholders on record as of August 17, and the picture emerging from Copenhagen is of a company comfortable with its own valuation, even as external observers grow increasingly restless.

The Deutsche Bank Verdict

Deutsche Bank's decision to move Novo Nordisk from "Hold" to "Sell" — while trimming its price target from 290 to 265 Danish kroner — was driven by two factors: the collapse of the cardiovascular candidate Ziltivekimab in a Phase 3 trial, and the intensifying competitive threat from Eli Lilly in the GLP-1 arena. The bank's revenue projections paint a sobering trajectory: 309 billion kroner for 2025, dipping to 299 billion in 2026, before a modest recovery to 304.25 billion the following year.

The Ziltivekimab failure is particularly galling. The antibody, designed to reduce cardiovascular risk in patients with elevated inflammatory markers, sat outside Novo Nordisk's core weight-loss franchise — but its demise reinforces a growing perception that the company's research engine is sputtering precisely when it needs to deliver. For a business whose valuation depends heavily on future growth, a pipeline setback of this magnitude is more than a footnote.

China and Europe Provide Counterweight

Yet the operational picture is far from uniformly bleak. The Chinese drug regulator has formally accepted the marketing application for the oral version of Wegovy, a development analysts estimate could unlock a market worth roughly 30 billion yuan — approximately $4.5 billion — over the next five to seven years. That follows the European Commission's approval on July 15 of the once-daily oral Wegovy for weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity.

Two regulatory advances in two of the most important growth markets outside the United States, within days of each other, is not nothing. But the competitive clock is ticking: Eli Lilly's oral GLP-1 candidate Orforglipron secured US approval back in April and is already under review in China — ahead of Novo Nordisk's own timeline in that region.

J.P. Morgan struck a more measured tone on August 25, maintaining its neutral stance while lifting its price target from 250 to 275 kroner, citing improved growth prospects for Ozempic and Wegovy beyond US borders. It's hardly a ringing endorsement, but it's a far cry from the alarm bells Deutsche Bank is ringing.

A Valuation That Demands Attention

Strip away the analyst debate and a striking fact emerges: after three years of share price decline, Novo Nordisk now trades at a significant discount to the broader pharmaceutical sector. The price-to-earnings ratio stands at roughly 11.2, against an industry average of 16.8 and a tighter comparison group trading at 49.6. A fair-value multiple of 25.4 would imply substantial undervaluation — provided the growth concerns don't materialize in full.

Management is also responding operationally to the intensifying competition in the obesity market. Wegovy is set to become available in vials, a direct counter to Eli Lilly's Zepbound, which overtook Wegovy in US prescription volumes last year. CEO Mike Doustdar, meanwhile, frames the GLP-1 opportunity as still nascent: of roughly 100 million Americans living with obesity, only 10 to 15 percent have tried such a medication, and he pegs the total addressable market at $50 billion.

The Technical Picture

The share price reaction to recent news has been muted. The stock trades at €39.66, virtually unchanged from the previous close of €39.67, though it remains down 12 percent over the past month and nearly 10 percent year-to-date. The 28 percent gap from the 52-week high of €54.86, reached in January, underscores the unease that has gripped the stock through recent months.

Yet the distance to the 200-day moving average of €40.21 is a mere 1.4 percent — the shares are hugging their medium-term trend rather than spiraling downward. That's a technical nuance that complicates the bearish narrative.

The Real Test Arrives in September

What ultimately resolves this tension may come on September 21, when Novo Nordisk hosts its capital markets day and presents its next-generation pipeline for obesity and diabetes therapies. Until then, the stock sits in an unusual position: fundamentals and analyst sentiment pointing in different directions, management's own buyback behavior suggesting confidence, and a valuation that looks increasingly reasonable if the growth story holds.

The Deutsche Bank downgrade deserves to be taken seriously — competitive pressure and pipeline risk are real. But the company's own actions — the relentless buybacks, the dividend, the regulatory wins in Europe and China — tell a story of a management team that believes the market has gotten ahead of itself in the wrong direction. One of them will be proven wrong.